Revance Therapeutics, Inc.
http://www.revance.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Revance Therapeutics, Inc.
What Pandemic Effect? US FDA’s 2021 Approval Class Is Off To Strong Start With 60+ Novel Candidates
Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.
US FDA 2020 Novel Approval Count Rises To 53 At CDER, Plus 5 New CBER Biologics
FDA reviewers stuck to established assessment practices during the coronavirus crisis and produced one of the agency’s largest yearly novel approval counts ever.
Keeping Track: Orladeyo, Danyelza, Imcivree Bring CDER 2020 Novel Approval Count Even With Full-Year 2019
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Revance Builds Therapeutics Credibility For DaxibotulinumtoxinA Ahead Of Aesthetics Launch
The long-acting neuromodulator improved symptoms of cervical dystonia in a Phase III trial with longer duration of efficacy versus older products; a launch for aesthetics is expected soon.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
- Topical Delivery
-
Drug Delivery
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Essentia Biosystems, Inc.
- HintMD